HDAC9 and non-small cell lung carcinoma: We noninvasively monitored the effects of cisplatin in the presence and absence of SAHA on HDAC class IIa activity in H441 (wild-type EGFR and KRAS codon 12 mutant) and PC14 (EGFR exon 19 deletion mutation) NSCLC xenograft tumors.